Abstract
A 56-year-old woman with a 40-year history of guttate flares of psoriasis associated with stress and infection as well as chronic asthma was treated with subcutaneous injections of ustekinumab, repeated after 1 month and then every 3 months. Her psoriasis completely resolved, and her capacity for exercise was markedly increased and asthma maintenance medications were no longer needed. Ustekinumab is a human monoclonal antibody that binds the p40 subunit of IL-12 and IL-23 to limit the progression of the Th1 and Th17 inflammatory immune responses that maintain many autoimmune and inflammatory diseases. Th17-related responses drive inflammation during late stages of chronic asthma and can also be blocked by ustekinumab. Blocking the underlying cytokine-mediated inflammatory responses for psoriasis with ustekinumab can also treat other chronic inflammatory diseases.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 63-66 |
| Number of pages | 4 |
| Journal | Journal of Dermatological Treatment |
| Volume | 25 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 1 2014 |
| Externally published | Yes |
Keywords
- Asthma
- Chronic inflammation
- IL-12p40
- Psoriasis
- Ustekinumab
ASJC Scopus subject areas
- Dermatology
